Mild ast elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort

Fernández-Carrillo, Carlos; Perelló, Christie; Herrera, Elba Llop; García‐Samaniego, J.; Romero, Míriam; Mostaza, José María; Ibáñez, Luis; Bañares, Rafael; Bighelli, Federico; Péron, Clara; Vázquez, Inmaculada Fernández; Castro, Olga Hernández; Albillos, Agustı́n; Lalueza, Antonio; Molina, Rosa Malo de; Múñez, Elena; Tejero, Elena; Panero, José Luis Calleja

doi:10.17235/reed.2021.8007/2021

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we similarly found that SARS-CoV-2 + rhinovirus coinfection, compared to SARS-CoV-2 mono-infection, was associated with lower laboratory biomarkers, specifically lower median ALT, AST, and CRP. These laboratory tests have been found to be raised in patients with more severe COVID-19 disease [33][34][35][36][37][38][39]. Further research is needed to investigate the discrepancy between 30-day mortality and laboratory biomarkers, but we hypothesize that respiratory symptoms may predominate early on in the disease course of patients with SARS-CoV-2 co-infections, which may necessitate hospital care before markers of systemic inflammation and organ involvement rise.…”

Section: Discussionmentioning

confidence: 96%

Clinical Outcomes Associated with SARS-CoV-2 Co-Infection with Rhinovirus and Adenovirus in Adults—A Retrospective Matched Cohort Study

Tran

Benitez

Shehadeh

et al. 2022

IJERPH

View full text Add to dashboard Cite

(1) Background: Respiratory co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses are common, but data on clinical outcomes and laboratory biomarkers indicative of disease severity are limited. We aimed to compare clinical outcomes and laboratory biomarkers of patients with SARS-CoV-2 alone to those of patients with SARS-CoV-2 and either rhinovirus or adenovirus. (2) Methods: Hospitalized patients co-infected with SARS-CoV-2 and rhinovirus and patients co-infected with SARS-CoV-2 and adenovirus were matched to patients infected with SARS-CoV-2 alone. Outcomes of interest were the cumulative incidences of mechanical ventilation use, intensive care unit (ICU) admission, 30-day all-cause mortality, and 30-day all-cause readmission from the day of discharge. We also assessed differences in laboratory biomarkers from the day of specimen collection. (3) Results: Patients co-infected with SARS-CoV-2 and rhinovirus, compared with patients infected with SARS-CoV-2, had significantly greater 30-day all-cause mortality (8/23 (34.8%) vs. 8/69 (11.6%), p = 0.02). Additionally, median alanine transaminase (13 IU/L vs. 24 IU/L, p = 0.03), aspartate transaminase (25 IU/L vs. 36 IU/L, p = 0.04), and C-reactive protein (34.86 mg/L vs. 94.68 mg/L, p = 0.02) on day of specimen collection were significantly lower in patients co-infected with SARS-CoV-2 and rhinovirus in comparison to patients infected with SARS-CoV-2 alone. Clinical outcomes and laboratory markers did not differ significantly between patients with SARS-CoV-2 and adenovirus co-infection and patients with SARS-CoV-2 mono-infection. (4) Conclusion: SARS-CoV-2 and rhinovirus co-infection, compared with SARS-CoV-2 mono-infection alone, is positively associated with 30-day all-cause mortality among hospitalized patients. However, our lack of significant findings in our analysis of patients with SARS-CoV-2 and adenovirus co-infection may suggest that SARS-CoV-2 co-infections have variable significance, and further study is warranted.

show abstract